An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.
Approximately one in 30 NIH-funded clinical trials—and more than 74,000 trial participants—were affected by grant funding disruptions caused by the Trump administration, according to an analysis in JAMA Internal Medicine.
